Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986470 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort A Part 1 | EXPERIMENTAL | - |
| Cohort A Part 2 | EXPERIMENTAL | - |
| Cohort A Part 3 | EXPERIMENTAL | - |
| Cohort B Part 1 | EXPERIMENTAL | - |
| Cohort B Part 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BMS-986470 | DRUG | Specified dose on specified days |
| Placebo | DRUG | Specified dose on specified days |
| Famotidine | DRUG | Specified dose on specified days |
| Pantoprazole | DRUG | Specified dose on specified days |
Inclusion Criteria: Cohort A: * Healthy male and female (who are not of childbearing potential) participants, as determined by the investigator based on medical history and other determinations. Females not of childbearing potential must have been amenorrhoeic for at least 12 months without an alt...
BMS-986470 is an investigational small molecule being developed for the treatment of anemia and sickle cell disease. It is currently in Phase 1 clinical development, with a study evaluating its effects in healthy volunteers and participants with sickle cell disease.
BMS-986470 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker symbol BMY. The company is conducting a Phase 1 clinical trial to evaluate the drug in healthy volunteers and patients with sickle cell disease.
BMS-986470 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The ongoing Phase 1 study is recruiting participants with sickle cell disease and healthy volunteers.
BMS-986470 is being studied in a Phase 1 clinical trial with the identifier NCT06481306. This randomized, double-blind, controlled study is evaluating the drug in healthy volunteers and participants with sickle cell disease, with an enrollment target of 224 participants across the United States, Canada, France, Italy, and the United Kingdom.
Yes, BMS-986470 is being studied in healthy volunteers as part of its Phase 1 clinical trial. The study, NCT06481306, includes healthy volunteers as well as participants with sickle cell disease, and is designed to evaluate the drug's safety and tolerability in both groups.